Venclexta (venetoclax) / AbbVie, Roche, Walter and Eliza Hall Institute  >>  Phase 3
Welcome,         Profile    Billing    Logout  

65 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Venclexta (venetoclax) / Roche, AbbVie
VENICE I, NCT02756611 / 2015-003667-11: A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

Completed
3b
258
Europe, Canada, US, RoW
Venetoclax, ABT-199, VENCLEXTA®
AbbVie
Chronic Lymphocytic Leukemia
04/19
03/22
VENICE II, NCT02980731 / 2016-001097-15: A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).

Completed
3b
210
Europe, RoW
Venetoclax, ABT-199, VENCLEXTA, VENCLYXTO
AbbVie
Chronic Lymphocytic Leukemia (CLL)
12/21
12/21
NCT03941964: A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Completed
3b
60
US
Venetoclax, ABT-199, VENCLEXTA, VENCLYXTO, Azacitidine, Vidaza, Decitabine, Dacogen
AbbVie
Acute Myeloid Leukemia (AML), Cancer
03/22
03/22
MURANO, NCT02005471 / 2013-002110-12: A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Checkmark 5 year data from MURANO trial for r/r CLL at ASH 2020
Dec 2020 - Dec 2020: 5 year data from MURANO trial for r/r CLL at ASH 2020
Checkmark Long-term follow-up data from MURANO study in r/r CLL at ASH 2019
Dec 2019 - Dec 2019: Long-term follow-up data from MURANO study in r/r CLL at ASH 2019
Checkmark MURANO trial data for r/r CLL at ASH 2018 [screenshot]
More
Completed
3
389
Europe, Canada, US, RoW
Bendamustine, Venetoclax, GDC-0199, ABT-199, Rituximab
Hoffmann-La Roche, AbbVie
Chronic Lymphocytic Leukemia
05/17
08/22
CLL14 study, NCT02242942 / 2014-001810-24: Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Checkmark 4 year data from trial in combination with obinutuzumab for previously untreated CLL at ASH 2020
Dec 2020 - Dec 2020: 4 year data from trial in combination with obinutuzumab for previously untreated CLL at ASH 2020
Checkmark From CLL-14 trial in combination with Gazyva in CLL
Sep 2020 - Sep 2020: From CLL-14 trial in combination with Gazyva in CLL
Checkmark From CLL-14 trial in combination with venetoclax in CLL at ASCO 2020
More
Active, not recruiting
3
445
Europe, Canada, US, RoW
Chlorambucil, Venetoclax, ABT-0199, GDC-0199, Obinutuzumab, GA-101; Gazyva
Hoffmann-La Roche, AbbVie, German CLL Study Group
Lymphocytic Leukemia, Chronic
08/18
08/25
VIALE-C, NCT03069352 / 2016-003900-30: A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Checkmark Data from VIALE-C trial in combination with low-dose cytarabine in AML
Feb 2020 - Feb 2020: Data from VIALE-C trial in combination with low-dose cytarabine in AML
Active, not recruiting
3
211
Europe, Canada, Japan, US, RoW
Placebo, Venetoclax, ABT-199, Venclexta, Cytarabine, Cytosar-U, Ara-C, Arabinosylcytosine
AbbVie
Acute Myeloid Leukemia (AML)
02/19
07/24
2018-002443-28: This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with already marketed drugs called Venetoclax and Obinutzumab in comparison to chemotherapy that is already in wide use for treatment of patients who have chronic lymphocytic leukemia and who have never been treated before.

Not yet recruiting
3
780
Europe, RoW
acalabrutinib, ACP-196, Capsule, hard, Concentrate for solution for infusion, Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Film-coated tablet, Powder for concentrate for solution for infusion, Gazyvaro, MABTHERA, Venclyxto
Acerta Pharma B.V., ACERTA PHARMA BV, AstraZeneca, Acerta Pharma B.V., AstraZeneca AB, ASTRAZENECA AB, Acerta BV
Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation, Previously untreated low-risk blood cancer, Diseases [C] - Cancer [C04]
 
 
2019-003327-37: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) without DEL (17P) or TP53 mutation Estudio para comparar la eficacia y seguridad de un régimen combinado de Venetoclax y Obinutuzumab versus fludarabina, ciclofosfamida y rituximab (FCR) / bendamustina y rituximab (BR) en pacientes FIT con leucemia linfocítica crónica (CLL) sin tratamiento previo sin DEL (17P) o mutación TP53

Not yet recruiting
3
165
Europe
Venclexta®, Venclyxto® or GDC-0199, Obinutuzumab, MabThera, Bendamustine, Cyclophosphamide, Fludarabine, Venclexta®, Venclyxto® or GDC- 0199, RO5537382, RO5072759, RO0452294, Film-coated tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Powder for solution for injection/infusion, Venclyxto® 10 mg film-coated tablets, Gazyvaro, MabThera 500 mg concentrate for solution for infusion, Venclyxto® 50 mg film-coated tablets, Venclyxto® 100 mg film-coated tablets
F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd
Chronic Lymphocytic Leukemia (CLL) Leucemia Linfocítica Crónica (LLC), CLL is a type of a cancer in which the bone marrow (BM) makes too many lymphocytes (a type of white blood cell) LLC es un tipo de cáncer en el cual la médula ósea (MO) produce demasiados linfocitos (un tipo de glóbulo blanco), Diseases [C] - Cancer [C04]
 
 
GLOW, NCT03462719 / 2017-004699-77: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Checkmark New data from the P3 GLOW study in combination with ibrutinib in 1L CLL/SLL at ASH 2022
Dec 2022 - Dec 2022: New data from the P3 GLOW study in combination with ibrutinib in 1L CLL/SLL at ASH 2022
Checkmark Data from GLOW trial in combination with Venclexta for CLL at ASH 2021
Dec 2021 - Dec 2021: Data from GLOW trial in combination with Venclexta for CLL at ASH 2021
Checkmark Presentation of data from GLOW trial in combination with Venclexta for CLL/SLL at EHA 2021
More
Active, not recruiting
3
211
Europe, Canada, US, RoW
Ibrutinib, Venetoclax, Chlorambucil, Obinutuzumab, Ibrutinib (as Subsequent Therapy)
Janssen Research & Development, LLC, Pharmacyclics LLC.
Leukemia, Lymphocytic, Chronic, B-Cell
02/21
04/27
BELLINI, NCT02755597 / 2015-004411-20: A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Checkmark From BELLINI trial in r/r multiple myeloma
Dec 2019 - Dec 2019: From BELLINI trial in r/r multiple myeloma
Completed
3
291
Europe, Canada, Japan, US, RoW
Venetoclax, VENCLEXTA, VENCLYXTO, Bortezomib, Velcade, Dexamethasone, Placebo for venetoclax
AbbVie, Genentech, Inc.
Relapsed/Refractory Multiple Myeloma
03/21
08/22
NCT04509622: A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)

Completed
3
14
Japan
Venetoclax, ABT-199, Venclexta, Cytarabine
AbbVie
Acute Myeloid Leukemia (AML)
04/21
04/21
SEQUOIA, NCT03336333 / 2017-001551-31: A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

Checkmark Topline results from SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia
Jul 2021 - Jul 2021: Topline results from SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia
Checkmark Presentation of data from SEQUOIA trial in CLL or SLL at ASH 2019
Dec 2019 - Dec 2019: Presentation of data from SEQUOIA trial in CLL or SLL at ASH 2019
Active, not recruiting
3
590
Europe, US, RoW
Zanubrutinib, BGB-3111, BRUKINSA, Bendamustine, Treanda, Ribomustin, and Levact, Rituximab, Rituxan, MabThera, Venetoclax, Venclexta, Venclyxto
BeiGene
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/21
09/26
2020-004360-26: Comparison of a fixed-duration treatment of acalabrutinib, venetoclax and obinutuzumab to a treatment of venetoclax and obinutuzumab in patients with high risk chronic lymphocytic leukemia Vergleich einer befristeten Therapie mit Acalabrutinib, Venetoclax und Obinutuzumab mit der Therapie von Venetoclax und Obinutuzumab bei Patienten mit chronischer lymphytischer Leukämie mit hohem Risiko

Not yet recruiting
3
178
Europe
Acalabrutinib, Obinutuzumab, Venetoclax, RO5072759, Capsule, hard, Concentrate for solution for infusion, Film-coated tablet, Calquence, Gazyvaro®, Venclyxto
German CLL Study Group (University of Cologne), AstraZeneca
Patients with previously untreated chronic lymphocytic leukemia with treatment requiring disease and at least one out of three risk factors (17p-deletion, TP53 mutation or Complex karyotype)., Patients with chronic lymphocytic leukaemia (blood cancer) in need of firstline treatment and at least one out of three risk factors., Diseases [C] - Cancer [C04]
 
 
NCT03406156: A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Completed
3
120
US
Obinutuzumab, Gazyva, Bendamustine, Bendeka, Venetoclax, Venclexta, ABT-199, GDC-0199
AbbVie
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
10/21
07/23
Viale-a, NCT02993523 / 2016-001466-28: A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

Checkmark Data from VIALE-A study in combination with azacitidine in 1L AML
Aug 2020 - Aug 2020: Data from VIALE-A study in combination with azacitidine in 1L AML
Checkmark Data from VIALE-A trial in combination with azacitidine for 1L unfit AML at EHA 2020
Jun 2020 - Jun 2020: Data from VIALE-A trial in combination with azacitidine for 1L unfit AML at EHA 2020
Checkmark From VIALE-A study in combination with azacitidine for 1L AML
More
Active, not recruiting
3
443
Europe, Canada, Japan, US, RoW
Azacitidine, Venetoclax, ABT-199, Placebo
AbbVie, Genentech, Inc.
Acute Myeloid Leukemia (AML)
12/21
09/24
2020-004453-71: Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with venetoclax or placebo in combination with chemotherapy. Behandlung von Patienten mit neudiagnostizierter Akuter myeloischer Leukämie (AML) oder Myelodysplastischem Syndrom (MDS) mit Venetoclax oder Placebo in Kombination mit Chemotherapy.

Not yet recruiting
3
650
Europe
Venetoclax, ABT-199, Film-coated tablet,
University Hospital Ulm, University Hospital Ulm, AbbVie Inc.
AML or MDS-EB2 AML oder MDS-EB2, Acute myeloid leukemia or myelodysplastic syndrome Akute myeloische Leukämie oder Myelodysplastisches Syndrom, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-003212-11: A study to evaluate if the addition of venetoclax to chemotherapy (fludarabine/cytarabine/gemtuzumab ozogamicin) improves the survival of children with relapsed acute myeloid leukemia. Een onderzoek om te evalueren of de toevoeging van venetoclax aan chemotherapie (fludarabine/cytarabine/gemtuzumab ozogamicine) de overleving verbetert van kinderen met teruggekeerde acute myeloïde leukemie.

Ongoing
3
98
Europe, RoW
Venetoclax for Oral suspension, Abbvie to provide, Tablet, Powder for oral suspension in sachet, Venclyxto
Princess Máxima Center, Princess Máxima Center for Paediatric Oncology, Princess Máxima Center for Oncology, ABBVIE INC., Leukemia & Lymphoma Society (LLS), Princess Máxima Center, Roche/Genentech
Children, adolescents, and young adults up to the age of 21 years with acute myeloid leukemia without FLT3/ITD mutation who are in:- Second relapse, who are sufficiently fit to undergo another round of intensive chemotherapy- First relapse who per investigator discretion cannot tolerate additional anthracycline containing chemotherapy. Kinderen, adolescenten en jongvolwassenen tot en met 21 jaar met acute myeloïde leukemie zonder FLT3/ITD-mutatie die zich in:- Tweede terugval, die voldoende fit zijn om nog een ronde intensieve chemotherapie te ondergaan- Eerste terugval die naar goeddunken van de onderzoeker geen aanvullende antracyclinebevattende chemotherapie kan verdragen., Pediatric patients, adolescentes and adults up to the age of 21 years who suffer from acute myeloid leukemia (a type of blood cancer) who have relapsed (returned after treatment). Pediatrische patiënten, adolescenten en volwassenen tot 21 jaar die lijden aan acute myeloïde leukemie (een vorm van bloedkanker) die is teruggekeerd (teruggekomen na behandeling)., Diseases [C] - Cancer [C04]
 
 
NCT04000698: Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias

Recruiting
3
25
RoW
Preparative regimen
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Refractory Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia
07/22
12/22
VIALE-M, NCT04102020 / 2019-002217-19: A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

Active, not recruiting
3
112
Europe, Canada, Japan, US, RoW
Venetoclax, ABT-199, GDC-0199, Venclexta, Azacitidine, CC-486
AbbVie, Roche-Genentech
Acute Myeloid Leukemia (AML)
09/22
04/25
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
ChiCTR2000041402: Venetoclax combined with azacitidine plus homoharringtonine versus venetoclax combined with azacitidine for relapsed/refractory acute myeloid leukemia: an open-label, multicentre, randomised phase 3 trial

Completed
3
162
 
venetoclax combined with azacitidine ;VAH regimen
Nanfang Hospital of Southern Medical University; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, The National Natural Science Foundation of China
Relapsed/refractory acute myeloid leukemia
 
 
NCT05457361: VAH Versus VA for Salvage Therapy of R/R-AML

Recruiting
3
162
RoW
VEN combined with azacitidine plus homoharringtonine, VEN combined with azacitidine
Nanfang Hospital of Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhongshan People's Hospital, Guangdong, China, Shenzhen Hospital of Southern Medical University, Peking University Shenzhen Hospital, Shenzhen Second People's Hospital, The Seventh Affiliated Hospital of Sun Yat-sen University, Southern Medical University, China, First People's Hospital of Chenzhou, The Affiliated Hospital of Qingdao University, First Affiliated Hospital of Guangxi Medical University
Venetoclax Combined With Azacitidine Plus Homoharringtonine, Venetoclax Combined With Azacitidine
12/22
12/23
NCT05654194: Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML

Recruiting
3
30
RoW
Azacitidine Combined With Venetoclax and ATRA group, AVA group
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
03/23
03/25
NCT05264883: Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML

Recruiting
3
170
RoW
Venetoclax-Decitabine/Azacitidine-Aclarubicin Association, Venetoclax-Decitabine/Azacitidine Association
The First Affiliated Hospital with Nanjing Medical University, The Affiliated Jiangning Hospital of Nanjing Medical University, Huai'an First People's Hospital, Yancheng First People's Hospital
Acute Myeloid Leukemia
06/23
02/25
NCT05177731: Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

Active, not recruiting
3
188
RoW
Venetoclax, Venclexta, Decitabine for Injection, Cytarabine, Ara-C, Idarubicin, IDA, Gilteritinib, XOSPATA
Chen Suning
AML, Adult, Chemotherapy Effect
02/24
12/24
GAIA, NCT02950051 / 2015-004936-36: Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Hourglass Jan 2021 - Dec 2021 : From CLL13 trial in combination with Venclexta for 1L CLL
Completed
3
926
Europe, RoW
Fludarabine, Fludura, Cyclophosphamide, Endoxan, Rituximab, MabThera, Rituxan, Bendamustine, Ribomustin, Levact, Venetoclax, Venclexta, Venclyxto, Obinutuzumab, Gazyva, Gazyvaro, Ibrutinib, Imbruvica
German CLL Study Group, Janssen-Cilag Ltd., Hoffmann-La Roche, AbbVie, Stichting Hemato-Oncologie voor Volwassenen Nederland, Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research, Cancer Trials Ireland, Israeli CLL Study Group
Chronic Lymphocytic Leukemia
02/24
02/24
ENHANCE-2, NCT04778397 / 2020-003949-11: Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

Calendar Jan 2023 - Dec 2024: Submission in combination with azacitidine in patients with TP53 mutant AML (based on ENHANCE-2 trial)
Calendar Jul 2024 - Dec 2024: Data from P3 ENHANCE-3 trial in combination with azacitidine for 1L unfit AML
Calendar Jul 2024 - Dec 2024: Data from ENHANCE-2 trial in combination with azacitidine in patients with TP53 mutant AML
Checkmark Pooled analysis data from ENHANCE-1 and ENHANCE-2 trials for COPD
Dec 2022 - Dec 2022: Pooled analysis data from ENHANCE-1 and ENHANCE-2 trials for COPD
More
Terminated
3
258
Europe, Canada, Japan, US, RoW
Magrolimab, GS-4721, Venetoclax, Azacitidine, Cytarabine, Daunorubicin, Idarubicin, Steroidal Eye Drops
Gilead Sciences
Acute Myeloid Leukemia
03/24
03/24
CRISTALLO, NCT04285567: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Active, not recruiting
3
166
Europe, US, RoW
Obinutuzumab, Gazyva, RO5072759, GA101, Venetoclax, Venclexta, RO5537382, GDC-0199, Fludarabine, Cyclophosphamide, Rituximab, MabThera, Rituxan, Bendamustine, Treanda, Levact, Ribomustin
Hoffmann-La Roche
Chronic Lymphocytic Leukemia (CLL)
03/24
07/26
NCT06361329: Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

Recruiting
3
81
RoW
Homoharringtonine, venetoclax, Cytarabine, G-CSF, Vindesine, Daunorubicin, cyclophosphamide, Dexamethasone, L-ASP
First Affiliated Hospital of Zhejiang University
ETP-ALL
03/26
03/27
ChiCTR2200059694: A Clinical Study of Decitabine + CAG regimen Combined with BCL2 Inhibitor Venetoclax in Treatment of Elderly or Unfit Patients with AML

Recruiting
3
50
 
D-CAG+VEN
West China Hospital, Sichuan University; West China Hospital of Sichuan University, none
acute myeloid leukemia
 
 
NCT06428019: A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Not yet recruiting
3
120
NA
Venetoclax, ABT-199, Acalabrutinib, Obinutuzumab
AbbVie
Chronic Lymphocytic Leukemia
10/26
10/26
NCT06073730: Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients

Not yet recruiting
3
154
RoW
Experimental: Venetoclax in combination with Decitabine (+-sorafenib), DEC3-VEN, Active Comparator: Standard dose of Venetoclax + Azacitidine
The Second Affiliated Hospital of Kunming Medical University
Elderly AML Patients, Unfit, New-diagnosis AML, Acute Myeloid Leukemia, Venetoclax, Decitabine
11/24
11/25
SYMPATICO, NCT03112174 / 2017-000129-12: Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma

Jan 2023 - Dec 2023: Data from SYMPATICO trial in combination with Venclexta for r/r MCL
Active, not recruiting
3
352
Europe, Canada, US, RoW
Ibrutinib, Venetoclax, Placebo Oral tablet to match Venetoclax
Pharmacyclics LLC., Janssen Research & Development, LLC
Mantle-Cell Lymphoma
11/24
11/24
REGAL, NCT04229979 / 2019-004134-42: Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Active, not recruiting
3
128
Europe, US, RoW
Galinpepimut-S, SLS-001, GPS, Azacitidine, Venetoclax, Decitabine, Cytarabine, Ara-C, Observation, GM-CSF, sargramostim, Montanide
Sellas Life Sciences Group
Acute Myeloid Leukemia
12/24
03/25
NCT04628026: Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Recruiting
3
650
Europe
Venetoclax, Placebo, Standard chemotherapy, Autologous stem cell transplantation, Allogeneic stem cell transplantation
University of Ulm, Stichting Hemato-Oncologie voor Volwassenen Nederland
Acute Myeloid Leukemia, Myelodysplastic Syndromes
02/25
02/31
Verona, NCT04401748 / 2020-000744-55: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

Hourglass Jul 2023 - Dec 2023 : Data readout from VERONA trial in combination with azacitidine for 1L high risk MDS
Active, not recruiting
3
531
Europe, Canada, Japan, US, RoW
Venetoclax, ABT-199, GDC-0199, Venclexta, Azacitidine, AZA, Placebo
AbbVie, Genentech, Inc.
Myelodysplastic Syndrome (MDS)
09/25
09/25
NCT03844048 / 2018-004356-38: An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Hourglass Jan 2019 - Dec 2019 : Initiation in front-line multiple myeloma
Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Venetoclax, ABT-199, Venclexta
AbbVie
Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer
02/26
02/26
ENHANCE-3, NCT05079230 / 2021-003434-36: Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

Calendar Jan 2023 - Dec 2024: Submission in combination with venetoclax and azacitidine for 1L unfit AML (based on ENHANCE-3 trial)
Calendar Jul 2024 - Dec 2024: Data from P3 ENHANCE-3 trial in combination with azacitidine for 1L unfit AML
Terminated
3
378
Europe, Canada, US, RoW
Magrolimab, GS-4721, Venetoclax, VENCLEXTA®, Azacitidine, Magrolimab Placebo
Gilead Sciences
Acute Myeloid Leukemia
04/24
04/24
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
ChiCTR2200061598: Venetoclax Combined with 5-Azacytidine (AZA) Alternating with Intermediate-dose AraC (LDAC) as Consolidation Therapy in Patients Aged 60 Years and above with Newly Diagnosed Acute Myeloid Leukemia (AML): A Prospective, Randomized, Open-Label, Multicenter Study

Not yet recruiting
3
160
 
Alternate consolidation therapy with venetoclax + azacitidine and medium-dose cytarabine for 3 cycles. 1 cycle includes: the first consolidation course (azacitidine 75mg/m2/d, d1~7; venetoclax 400mg/d, d1-d28), the second consolidation course (cytarabine 0.5~1g/m2 q12h*3d) ;6 courses of consolidation therapy with venetoclax + azacitidine ( (azacitidine 75mg/m2/d, d1~7; venetoclax 400mg/d, d1-d28))
Suzhou Hongci Hematology Hospital; Suzhou Hongci Hematology Hospital, SLT201911 - Clinical Trial Capability Improvement Project of Hematology Clinical Professional Group of the First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
 
 
CANOVA, NCT03539744 / 2017-003838-88: A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Jan 2023 - Jun 2023: Data from CANOVA trial for r/r multiple myeloma
Active, not recruiting
3
265
Europe, Canada, Japan, US, RoW
Pomalidomide, Pomalyst, Dexamethasone, Venetoclax, ABT-199, GDC-0199
AbbVie, Roche-Genentech
Multiple Myeloma
08/26
08/26
ChiCTR2200059663: A multicenter, prospective, randomized controlled clinical study comparing the efficacy of VHAA and DA regimens in the treatment of adult acute myeloid leukemia

Not yet recruiting
3
176
 
Homoharringtonine 2mg/m2/d, qd, intramuscular injection or intravenous drip, d1~d5; Cytarabine 100mg/m2/d, q12h, subcutaneous injection or intravenous drip, qd, d1~d5, Aclarubicin 12mg/m2/d, intravenous injection, d1~d5, venetoclax 100mg d2, 200mg d3, 300mg d4~d10, qd, oral ;Daunorubicin 60mg/ m2/d, intravenous injection, qd, d1~3; Ara-C 100mg/ m2/d, intravenous injection, qd or subcutaneous injection, two times, 12 hours apart, d1~d7
First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Medical College of Zhejiang University, Zhejiang Provincial Clinical Research Center For Hematological disorders
acute myeloid leukemia
 
 
NCT05197192 / 2020-004360-26: A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Recruiting
3
650
Europe
Obinutuzumab, Gazyva, Gazyvaro, Venetoclax, Venclexta, Venclyxto, Acalabrutinib, Calquence
German CLL Study Group, AstraZeneca
Chronic Lymphocytic Leukemia
05/26
02/27
VIALE-T, NCT04161885 / 2019-002621-30: A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

Active, not recruiting
3
424
Europe, Canada, Japan, US, RoW
Venetoclax, ABT-199, GDC-0199, VENCLEXTA, Azacitidine, Best Supportive Care (BSC)
AbbVie
Acute Myeloid Leukemia (AML), Cancer
11/26
11/26
NCT05211856: Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Recruiting
3
780
Europe, Canada, US, RoW
Acalabrutinib, Calquence (acalabrutinib), Venetoclax, Venclyxto, Venclexta, Chemoimmunotherapy, Obinutuzumab, Gazyva, Gazyvaro
AstraZeneca
Chronic Lymphocytic Leukemia
01/27
01/27
ACE-CL-311, NCT03836261: Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Calendar Jan 2027 - Mar 2027: Last patient dosing of P3 ACE-CL-311 trial in combination with venetoclax for previously untreated CLL
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with venclexta and obinutuzumab for 1L CLL (based on AMPLIFY trial)
Calendar Jan 2024 - Dec 2024: Data from AMPLIFY trial in combination with Calquence and obinutuzumab for previously untreated CLL
Hourglass Jul 2022 - Dec 2022 : From P3 ACE-CL-311 trial in combination with Venclexta for 1L CLL
Active, not recruiting
3
984
Europe, Canada, US, RoW
Acalabrutinib, Calquence (acalabrutinib), Venetoclax, Venclyxto, Venclexta, Chemoimmunotherapy, Obinutuzumab, Gazyva, Gazyvaro
Acerta Pharma BV, AstraZeneca
Chronic Lymphocytic Leukemia
01/27
01/27
APAL2020D, NCT05183035 / 2021-003212-11: Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Recruiting
3
98
Europe, Canada, US, RoW
Fludarabine, Cytarabine, Gemtuzumab Ozogamicin, Azacitidine, Venetoclax
LLS PedAL Initiative, LLC, Princess Maxima Center for Pediatric Oncology (European Sponsor), AbbVie, Roche-Genentech, EuPAL
Acute Myeloid Leukemia
02/27
02/32
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting
3
897
Europe, RoW
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro
German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG)
Chronic Lymphoid Leukemia
03/27
03/27
MAJIC, NCT05057494 / 2021-003936-10: A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active, not recruiting
3
607
Europe, US, RoW
Acalabrutinib, Venetoclax, Obinutuzumab
AstraZeneca
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
07/27
04/29
A041702, NCT03737981: Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Active, not recruiting
3
454
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Observation, Inspection, Visual Inspection, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/27
06/27
NCT03701282: Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

Active, not recruiting
3
720
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/28
05/28
IMbrella B, NCT03768063 / 2018-003352-20: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Recruiting
3
1000
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Alectinib, Alecensa, Cobimetinib, Cotellic, Vemurafenib, Zelboraf, FAP IL2V, simlukafusp alfa, Venetoclax, Venclexta, Enzalutamide, Xtandi, Pembrolizumab, Keytruda, Sunitinib, Sutent, Niraparib, Zejula, Cabozantinib, Cometriq, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd, F. Hoffmann- La Roche Ltd
Cancer
07/28
07/28
EVOLVE CLL/SLL, NCT04269902: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), Study

Recruiting
3
247
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
10/28
10/28
CELESTIAL-TNCLL, NCT06073821: Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Recruiting
3
640
Europe, Canada, US, RoW
Sonrotoclax, BGB-11417, Zanubrutinib, BGB-3111, Venetoclax, Obinutuzumab
BeiGene
CLL
02/32
12/32
BELLWAVE-010, NCT05947851: A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/)

Recruiting
3
720
Europe, Canada, US, RoW
Nemtabrutinib, ARQ 531, MK-1026, Venetoclax, ABT-199, GDC-0199, Rituximab
Merck Sharp & Dohme LLC
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL
06/33
06/33
2019-000270-29: The trial will investigate whether three months of treatment with a combination of two types of medication given as tablets can reduce the risk of infection and the need for regular CLL treatment when given to newly diagnosed CLL patients.

Not yet recruiting
2/3
212
Europe
Venetoclax 10 mg, Venetoclax 50 mg, Venetoclax 100 mg, Accalabrutinib, ACP-196, Tablet, Capsule, Venclyxto
Rigshopitalet/Copenhagen University Hospital, Novo Nordisk Foundation, Pharma Acerta, Abbvie
Chronic Lymphocytic Leukemia, Chronic cancer of white blood cells and bone marrow, Diseases [C] - Cancer [C04]
 
 
ULTRA-V, NCT03801525: Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL

Hourglass Jan 2021 - Mar 2021 : Completion of enrollment in P2 ULTRA-V trial in combination with umbralisib and venetoclax for CLL
Terminated
2/3
277
US
Ublituximab, TG-1101, Umbralisib, TGR-1202, UKONIQ, Venetoclax, Venclexta®
TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/22
12/22
NCT06285136: Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult

Not yet recruiting
2/3
40
RoW
DEC3-VEN
The Second Affiliated Hospital of Kunming Medical University, Institute of hematology hospital,Chinese Academy of Medical Sciences, Handan Central Hospital, Taian City Central Hospital, Tianjin People's Hospital, Guizhou Provincial People's Hospital, Central South University, Western Theater General Hospital, First Affiliated Hospital of Guangxi Medical University, Chengdu Jingdongfang Hospital
Acute Myeloid Leukemia, Adult
03/26
03/26
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
06/24
 
NCT05356169: Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia

Not yet recruiting
2/3
300
NA
with or without venetoclax
Institute of Hematology & Blood Diseases Hospital
Acute Myeloid Leukemia
06/24
06/27
VHA, NCT05805098: Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML

Recruiting
2/3
60
RoW
Venetoclax, VEN, Homoharringtonine, HHT, Cytarabine
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
03/25
03/28
NCT05939180: VA vs DA for Newly Diagnosed Hig-risk AML

Recruiting
2/3
116
RoW
Venetoclax Oral Tablet, venetoclax plus azacytidine, Daunorubicin, daunorubicin plus cytarabine
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
10/25
10/27
A051701, NCT03984448: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Active, not recruiting
2/3
363
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Lumbar Puncture, LP, Spinal Tap, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
04/28
04/28
NCT05404906: AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

Recruiting
2/3
124
RoW
Azacitidine, 5-Azacytidine, Venetoclax, ABT-199, GDC-0199, Venclexta, Supportive care
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia (AML) in Remission
06/28
06/30
NCT03868722: Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment

Recruiting
2/3
212
Europe
Acalabrutinib, Calquence, Venetoclax, Venclexta, Venclyxto
Rigshospitalet, Denmark, Stichting Hemato-Oncologie voor Volwassenen Nederland, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Karolinska Institutet
CLL
07/29
07/30

Download Options